U.S. pharma huge copyright scrapped two experimental weight loss capsules previous 12 months—a once-each day tablet, lotiglipron, due to elevated liver enzymes plus a two times-each day tablet, danuglipron, resulting from powerful side effects—but CEO Albert Bourla has reported the c